7 to 12 of 143 results
The Leiden-based biotech company Ncardia is teaming up with LUMC on the development of a new platform enabling the automated production of 3D cardiac microtissues. This platform enables efficient and reliable testing of medicines and their effects.
Research by the LUMC shows that CD8 T cells, which attack diseased cells such as cancer cells, function better when their cell division is temporarily paused. This discovery provides new insight into how cancer treatments can be combined more effectively.
Nicotine use is responsible for 26,500 emergency room visits per year and may play a role in nearly 193,000 other visits. Targeted policies could significantly reduce the pressure on emergency care.
Read more about Nicotine policy approach could save 26,000 emergency room visits per year
Recent trials show that the PanFlu nasal spray, developed by Leyden Labs, is showing promising results and has the potential to be used as a preventive tool against new pandemics.
Leiden plays a key role in the future earning capacity of the Netherlands. With leading knowledge institutions and the Leiden Bio Science Park, the city connects science, entrepeneurship and impact, making it a strong location for international congresses
Researchers at the LUMC have tested the drug IC7Fc, which combats cardiovascular disease. The drug could be an important breakthrough and step forward in the fight against cardiovascular disease, which kills 17 million people worldwide every year.
